JNJ-61803534

Cat. No.: HY-139780

CAS No.: 1917306-14-9

Molecular Formula: $C_{23}H_{23}Cl_2F_6N_3O_4S$

Molecular Weight: 622.41

Target: ROR

Pathway: Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor

Storage:

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 300 mg/mL (482.00 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	1.6067 mL	8.0333 mL	16.0666 mL
	5 mM	0.3213 mL	1.6067 mL	3.2133 mL
	10 mM	0.1607 mL	0.8033 mL	1.6067 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

JNJ-61803534 is a potent and orally active RORγt inverse agonist with an IC_{50} of 9.6 nM. JNJ-61803534 has anti-inflammatory activity. JNJ-61803534 inhibits IL-17A production in human CD4+ T cells under Th17 differentiation conditions [1].

IC_{50} & Target

RORγt

In Vitro

JNJ-61803534 inhibits RORγt transcription in HEK-293 T cells transfected with vectors encoding RORγt, with an IC_{50} of 9.6 nM[1].

JNJ-61803534 (1 nM-1 μM) inhibits IL-17A, IL-17F IFNγ and IL-22 production in CD4+ T cells isolated from human blood[1].

JNJ-61803534 does not impact in vitro Treg differentiation in CD4+ T cells[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

JNJ-61803534 (100 mg/kg, p.o.) inhibits ex vivo stimulated IL-17A production in the blood of mice[1].

JNJ-61803534 (3-100 mg/kg BID or 60 mg/kg QD, p.o.) alleviates inflammation, cartilage damage, bone destruction in mouse collagen-induced arthritis (CIA) model[1].

JNJ-61803534 (30 and 100 mg/kg, p.o.) alleviates Imiquimod (HY-B0180)-induced dermal psoriatic-like inflammation in mice [1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Mouse collagen-induced arthritis (CIA) model[1]
Dosage:	3-100 mg/kg BID or 60 mg/kg QD
Administration:	Oral administration (p.o.)
Result:	Decreased clinical arthritis scores and hind paw histopathology scores.

REFERENCES

[1]. Xue X, et al. Preclinical and clinical characterization of the RORγt inhibitor JNJ-61803534. Sci Rep. 2021 May 26;11(1):11066.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA